ESR1 and breast cancer: The principal application of prognostic signatures such as Oncotype DX and EarlyR is to discriminate between ER+/LN− breast cancer patients who have sufficiently high risk of relapse to justify treating with chemotherapy and those with good prognosis who are unlikely to benefit from chemotherapy.